ImmunityBio, Inc. IBRX Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s total revenue?
- ImmunityBio, Inc. (IBRX) reported total revenue of $44.21M in Q1 2026.
- How has ImmunityBio, Inc.'s total revenue changed year-over-year?
- ImmunityBio, Inc.'s total revenue increased by 167.6% year-over-year, from $16.52M to $44.21M.
- What is the long-term trend for ImmunityBio, Inc.'s total revenue?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s total revenue has grown at a 231.9% compound annual growth rate (CAGR), from $934K to $113.29M.
- What does total revenue mean?
- The total amount of money generated by business operations before any expenses are deducted.
- How do you interpret total revenue?
- An increase indicates successful product adoption or expansion of commercial partnerships, while a decrease may signal market saturation or loss of competitive advantage.
- How does total revenue compare across companies?
- Biotech peers at similar clinical stages often show lower revenue until commercialization, while mature peers show steady growth.